NASDAQ:RSLS

ReShape Lifesciences (RSLS) Stock Forecast, Price & News

$0.34

0.00 (0.00%)

(As of 10/2/2023 ET)

Compare

Today's Range: $0.27
▼
$0.34
50-Day Range: $0.34
▼
$1.47
52-Week Range: $0.21
▼
$22.40

Volume: 967,360 shs
Average Volume: 457,439 shs
Market Capitalization: $1.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

ReShape Lifesciences MarketRank™ Forecast

Analyst Rating: 0.00 Rating Score
Upside/Downside: 2,252.9% Upside
$8.00 Price Target
Short Interest: Healthy
4.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.77
Based on 3 Articles This Week
Insider Trading: Selling Shares
$156 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.53 out of 5 stars

2.0

Analyst's Opinion

Price Target Upside/Downside
According to analysts' consensus price target of $8.00, ReShape Lifesciences has a forecasted upside of 2,252.9% from its current price of $0.34.
Amount of Analyst Coverage
ReShape Lifesciences has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.82% of the float of ReShape Lifesciences has been sold short.
Short Interest Ratio / Days to Cover
ReShape Lifesciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ReShape Lifesciences has recently increased by 335.44%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ReShape Lifesciences does not currently pay a dividend.
Dividend Growth
ReShape Lifesciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RSLS.

2.7

News and Social Media Coverage

News Sentiment
ReShape Lifesciences has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for ReShape Lifesciences this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for RSLS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
1 people have added ReShape Lifesciences to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ReShape Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $156.00 in company stock.
Percentage Held by Insiders
Only 1.60% of the stock of ReShape Lifesciences is held by insiders.
Percentage Held by Institutions
Only 3.01% of the stock of ReShape Lifesciences is held by institutions.

0.6

Earnings and Valuation

Price to Book Value per Share Ratio
ReShape Lifesciences has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ReShape Lifesciences (NASDAQ:RSLS) Stock

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

RSLS Price History

30 days | 90 days | 365 days | Advanced Chart

RSLS Stock News Headlines

September 29, 2023 | finance.yahoo.com

ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering

September 22, 2023 | finance.yahoo.com

ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI

October 2, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>

September 19, 2023 | finance.yahoo.com

ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System

September 14, 2023 | finanznachrichten.de

ReShape Lifesciences Inc: ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device

September 14, 2023 | finance.yahoo.com

ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device

September 13, 2023 | uk.finance.yahoo.com

RSLS - ReShape Lifesciences Inc.

August 9, 2023 | insidermonkey.com

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2023 Earnings Call Transcript

October 2, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

August 9, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Augmedix (AUGX), ReShape Lifesciences (RSLS)

August 8, 2023 | finance.yahoo.com

Q2 2023 ReShape Lifesciences Inc Earnings Call

August 8, 2023 | finance.yahoo.com

ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update

August 3, 2023 | finance.yahoo.com

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update

June 29, 2023 | finanznachrichten.de

ReShape Lifesciences Inc: ReShape Lifesciences Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software

June 29, 2023 | finance.yahoo.com

ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software

June 28, 2023 | finance.yahoo.com

ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting

June 27, 2023 | finanznachrichten.de

ReShape Lifesciences Inc: ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band 2.0

June 14, 2023 | finance.yahoo.com

ReShape Lifesciences® to Participate in Investor and Industry Conferences in June

May 16, 2023 | finance.yahoo.com

Q1 2023 ReShape Lifesciences Inc Earnings Call

May 15, 2023 | finance.yahoo.com

ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update

May 11, 2023 | finance.yahoo.com

ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update

April 28, 2023 | marketwatch.com

ReShape Lifesciences(R) to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the Keystone Symposia on Type 2 Diabetes

April 25, 2023 | finance.yahoo.com

ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update

April 25, 2023 | markets.businessinsider.com

ReShape Lifesciences (RSLS) Gets a Buy from Maxim Group

April 19, 2023 | finance.yahoo.com

Investors Continue Waiting On Sidelines For ReShape Lifesciences Inc. (NASDAQ:RSLS)

April 11, 2023 | seekingalpha.com

ReShape Lifesciences gets patent for Obalon balloon system

March 30, 2023 | benzinga.com

Reshape Lifesciences Stock (NASDAQ:RSLS), Guidance and Forecast

See More Headlines

Receive RSLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

RSLS Company Calendar

Last Earnings: 8/07/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:RSLS
CUSIP: 29365M20
CIK: 1371217
Web: www.reshapelifesciences.com
Phone: (949) 429-6680
Fax: N/A
Employees: 40
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +2,252.9%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,210,000.00
Net Margins: -333.14%
Pretax Margin: -336.98%
Return on Equity: -283.51%
Return on Assets: -163.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.39
Quick Ratio: 1.65

Sales & Book Value

Annual Sales: $10.45 million
Price / Sales: 0.11
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.05 per share
Price / Book: 0.05

Miscellaneous

Outstanding Shares: 3,452,000
Free Float: 3,172,000
Market Cap: $1.17 million
Optionable: Not Optionable
Beta: -0.17

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Dan W. Gladney (Age 70)
Exec. Chair
Comp: $95.26k

Mr. Paul F. Hickey (Age 58)
CEO, Pres & Director
Comp: $158.08k

Mr. Thomas Stankovich (Age 62)
Chief Financial Officer
Comp: $555.84k

Dr. Mark B. Knudson Ph.D. (Age 74)
Co-Founder and Special Advisor to the CEO

Dr. Katherine S. Tweden Ph.D. (Age 62)
Co-Founder

Mr. Al Diaz
VP of Operations and R&D

Dr. Dov Gal D.V.M.
DVM, M.B.A., MBA, VP of Regulatory Clinical Quality & Compliance Officer

Jody B. Dahlman
Director of Communications

Mr. Naqeeb A. Ansari (Age 62)
Sr. VP of Global Commercial Operations

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

RSLS Stock - Frequently Asked Questions

What is ReShape Lifesciences' stock price forecast for 2023?: 0 analysts have issued twelve-month target prices for ReShape Lifesciences' stock. Their RSLS share price forecasts range from $8.00 to $8.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 2,252.9% from the stock's current price.
View analysts price targets for RSLS or view top-rated stocks among Wall Street analysts.
How have RSLS shares performed in 2023?: ReShape Lifesciences' stock was trading at $6.74 at the beginning of 2023. Since then, RSLS stock has decreased by 95.0% and is now trading at $0.34.
View the best growth stocks for 2023 here.
Are investors shorting ReShape Lifesciences?: ReShape Lifesciences saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 158,500 shares, an increase of 335.4% from the August 31st total of 36,400 shares. Based on an average trading volume of 150,100 shares, the days-to-cover ratio is currently 1.1 days. Currently, 4.8% of the company's stock are short sold.
View ReShape Lifesciences' Short Interest.
When is ReShape Lifesciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our RSLS earnings forecast.
How were ReShape Lifesciences' earnings last quarter?: ReShape Lifesciences Inc. (NASDAQ:RSLS) announced its earnings results on Monday, August, 7th. The medical device company reported ($1.08) earnings per share for the quarter. The medical device company had revenue of $2.25 million for the quarter. ReShape Lifesciences had a negative net margin of 333.14% and a negative trailing twelve-month return on equity of 283.51%.

When did ReShape Lifesciences' stock split?: ReShape Lifesciences's stock reverse split before market open on Thursday, December 22nd 2022. The 1-50 reverse split was announced on Thursday, December 22nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
What is ReShape Lifesciences' stock symbol?: ReShape Lifesciences trades on the NASDAQ under the ticker symbol "RSLS."
How do I buy shares of ReShape Lifesciences?: Shares of RSLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ReShape Lifesciences' stock price today?: One share of RSLS stock can currently be purchased for approximately $0.34.
How much money does ReShape Lifesciences make?: ReShape Lifesciences (NASDAQ:RSLS) has a market capitalization of $1.17 million and generates $10.45 million in revenue each year.
How can I contact ReShape Lifesciences?: ReShape Lifesciences' mailing address is 1001 Calle Amanecer, San Clemente CA, 92673. The official website for the company is www.reshapelifesciences.com. The medical device company can be reached via phone at (949) 429-6680 or via email at ir@reshapelifesci.com.

This page (NASDAQ:RSLS) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial